ValiRx - Signs Letter of Intent to Sub-License VAL201
VAL Tue, 02 Nov 2021, 05:00pm GMT
ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.
Industry: Health Care
Contact: +44 (0)2476 796496
Dr Suzy Dilly, CEO of ValiRx discusses the recently signed letter of intent with TheoremRx Inc to sub-license ValiRx's legacy asset VAL201.